Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 11 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

18%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 1
5(45.5%)
Phase 2
4(36.4%)
Phase 3
2(18.2%)
11Total
Phase 1(5)
Phase 2(4)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials
NCT05112991Phase 2Recruiting

Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

Role: lead

NCT06123754Phase 3Recruiting

Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC

Role: lead

NCT03667170Phase 2Recruiting

KN035 for dMMR/MSI-H Advanced Solid Tumors

Role: lead

NCT04891198Phase 2Recruiting

ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors

Role: lead

NCT04910386Phase 2Not Yet Recruiting

Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers

Role: lead

NCT05024214Phase 1Recruiting

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Role: lead

NCT03478488Phase 3Active Not Recruiting

Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC

Role: lead

NCT05849311Phase 1Completed

Phase I Trial of Envafolimab for Healthy Male Subjects

Role: lead

NCT03101488Phase 1Completed

Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors

Role: lead

NCT03248843Phase 1Completed

A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors

Role: lead

NCT02827968Phase 1Completed

Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors

Role: lead

All 11 trials loaded